Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider James William Burns sold 2,932 shares of the business’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the sale, the insider directly owned 31,718 shares in the company, valued at approximately $859,240.62. This represents a 8.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Agios Pharmaceuticals Stock Down 0.1%

NASDAQ:AGIO traded down $0.04 during trading hours on Friday, reaching $27.18. The company had a trading volume of 891,433 shares, compared to its average volume of 1,512,286. The stock has a 50-day moving average of $32.20 and a two-hundred day moving average of $35.96. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00. The firm has a market capitalization of $1.58 billion, a PE ratio of -3.88 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company had revenue of $12.88 million for the quarter, compared to the consensus estimate of $10.49 million. During the same quarter in the previous year, the company earned $16.22 EPS. The firm’s revenue for the quarter was up 43.3% compared to the same quarter last year. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AGIO has been the subject of several recent analyst reports. Citigroup reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday, December 26th. Bank of America increased their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. HC Wainwright lifted their price objective on Agios Pharmaceuticals from $48.00 to $62.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday. Finally, JPMorgan Chase & Co. decreased their target price on Agios Pharmaceuticals from $37.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Wellington Management Group LLP boosted its position in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares during the last quarter. TCG Crossover Management LLC lifted its stake in shares of Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after acquiring an additional 733,038 shares during the period. SCS Capital Management LLC bought a new position in Agios Pharmaceuticals in the first quarter valued at about $17,905,000. Balyasny Asset Management L.P. bought a new position in Agios Pharmaceuticals in the third quarter valued at about $19,889,000. Finally, Adage Capital Partners GP L.L.C. increased its position in Agios Pharmaceuticals by 145.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company’s stock worth $21,770,000 after purchasing an additional 440,000 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.